Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
Immune checkpoint inhibitor (ICI) therapy targeting anti-programmed cell death-1 (anti-PD-1) or its ligand (anti-PD-L1) is the backbone of numerous combination regimens aimed at improving the objective response and survival of patients with hepatocellular carcinoma (HCC). Clinical trials of immuno-oncology regimens in other cancer types have shed light on issues of study design, including how to choose candidate regimens based on early-phase trial results, statistical considerations in trials with multiple primary endpoints, and the importance of predictive biomarkers.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Ann-Lii Cheng, Chiun Hsu, Stephen L. Chan, Su-Pin Choo, Masatoshi Kudo Tags: Review Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Clinical Trials | Gastroenterology | Hepatocellular Carcinoma | Liver Cancer | Statistics | Study